NO20056170L - Kreftkombinasjonsterapi omfattende AZD2171 of ZD1839 - Google Patents

Kreftkombinasjonsterapi omfattende AZD2171 of ZD1839

Info

Publication number
NO20056170L
NO20056170L NO20056170A NO20056170A NO20056170L NO 20056170 L NO20056170 L NO 20056170L NO 20056170 A NO20056170 A NO 20056170A NO 20056170 A NO20056170 A NO 20056170A NO 20056170 L NO20056170 L NO 20056170L
Authority
NO
Norway
Prior art keywords
azd2171
human
combination therapy
cancer
antiangiogenic
Prior art date
Application number
NO20056170A
Other languages
English (en)
Inventor
Stephen Robert Wedge
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of NO20056170L publication Critical patent/NO20056170L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Iron Core Of Rotating Electric Machines (AREA)

Abstract

Foreliggende oppfinnelse angår en metode for produksjon av en antiangiogen og/eller vaskulær permeabilitetsreduserende effekt hos et varmblodig dyr så som et menneske som eventuelt behandles med ioniserende sfråling, spesielt en metode for behandling av kreft, spesielt kreft som involverer en fast tumor, som omfatter administrering av AZD 2171 i kombinasjon med ZD 1839; et farmasøytisk preparat omfattende AZD 2171 og ZD 1839; et kombinasjonsprodukt omfattende AZD 2171 og ZD 1839 for anvendelse ved en metode for behandling av en menneske- eller dyrekropp ved terapi; et sett omfattende AZD 2171 og ZD 1839; anvendelse av AZD 2171 og ZD 1839 ved fremstilling av et medikament for anvendelse for produksjon av en antiangiogen og eller vaskulær permeabilitetsreduserende effekt hos et varmblodig dyr så som et menneske som eventuelt behandles med ioniserende sfråling.
NO20056170A 2003-07-10 2005-12-23 Kreftkombinasjonsterapi omfattende AZD2171 of ZD1839 NO20056170L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0316127.0A GB0316127D0 (en) 2003-07-10 2003-07-10 Combination therapy
PCT/GB2004/002944 WO2005004872A1 (en) 2003-07-10 2004-07-08 Cancer combination therapy comprising azd2171 and zd1839

Publications (1)

Publication Number Publication Date
NO20056170L true NO20056170L (no) 2006-02-08

Family

ID=27741907

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20056170A NO20056170L (no) 2003-07-10 2005-12-23 Kreftkombinasjonsterapi omfattende AZD2171 of ZD1839

Country Status (24)

Country Link
US (2) US20060167024A1 (no)
EP (1) EP1653964B1 (no)
JP (1) JP2007526888A (no)
KR (1) KR20060033785A (no)
CN (1) CN100415236C (no)
AT (1) ATE409039T1 (no)
AU (1) AU2004255024B2 (no)
BR (1) BRPI0412408A (no)
CA (1) CA2531620C (no)
DE (1) DE602004016754D1 (no)
DK (1) DK1653964T3 (no)
ES (1) ES2313033T3 (no)
GB (1) GB0316127D0 (no)
HK (1) HK1089667A1 (no)
HR (1) HRP20080597T3 (no)
IL (1) IL172683A0 (no)
MX (1) MXPA06000412A (no)
NO (1) NO20056170L (no)
NZ (1) NZ544270A (no)
PL (1) PL1653964T3 (no)
PT (1) PT1653964E (no)
SI (1) SI1653964T1 (no)
WO (1) WO2005004872A1 (no)
ZA (1) ZA200600184B (no)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0008269D0 (en) 2000-04-05 2000-05-24 Astrazeneca Ab Combination chemotherapy
GB0218526D0 (en) * 2002-08-09 2002-09-18 Astrazeneca Ab Combination therapy
GB0310401D0 (en) * 2003-05-07 2003-06-11 Astrazeneca Ab Therapeutic agent
AU2005225192B2 (en) * 2004-03-23 2008-10-09 Astrazeneca Ab Combination therapy
GB0406445D0 (en) * 2004-03-23 2004-04-28 Astrazeneca Ab Combination therapy
NZ564189A (en) * 2005-07-06 2011-04-29 Astrazeneca Ab Combination therapy of cancer with AZD2171 and gemcitabine
NZ568812A (en) * 2005-12-22 2011-09-30 Astrazeneca Ab Combination of AZD2171 and pemetrexed
WO2009118560A1 (en) * 2008-03-28 2009-10-01 Astrazeneca Ab Combination therapy 038
EP2113255A1 (en) * 2008-05-02 2009-11-04 f-star Biotechnologische Forschungs- und Entwicklungsges.m.b.H. Cytotoxic immunoglobulin

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU762615B2 (en) * 1998-06-15 2003-07-03 Arch Development Corporation Combination of radiotherapy and anti-angiogenic factors
KR20080015482A (ko) * 1999-02-10 2008-02-19 아스트라제네카 아베 혈관형성 억제제로서의 퀴나졸린 유도체
EE200200549A (et) * 2000-03-31 2004-02-16 Angiogene Pharmaceuticals Ltd. Jagatud doosi teraapia veresooni kahjustava aktiivsusega
GB0008269D0 (en) * 2000-04-05 2000-05-24 Astrazeneca Ab Combination chemotherapy
EP1339458B1 (en) * 2000-11-22 2007-08-15 Novartis AG Combination comprising an agent decreasing vegf activity and an agent decreasing egf activity
CA2473572C (en) * 2002-02-01 2011-05-10 Astrazeneca Ab Quinazoline compounds

Also Published As

Publication number Publication date
HRP20080597T3 (en) 2008-12-31
EP1653964A1 (en) 2006-05-10
US20100179142A1 (en) 2010-07-15
ZA200600184B (en) 2007-04-25
CA2531620C (en) 2011-09-27
IL172683A0 (en) 2006-04-10
ATE409039T1 (de) 2008-10-15
ES2313033T3 (es) 2009-03-01
MXPA06000412A (es) 2006-03-17
EP1653964B1 (en) 2008-09-24
CN100415236C (zh) 2008-09-03
DK1653964T3 (da) 2009-01-05
JP2007526888A (ja) 2007-09-20
SI1653964T1 (sl) 2009-02-28
DE602004016754D1 (de) 2008-11-06
CN1819831A (zh) 2006-08-16
AU2004255024A1 (en) 2005-01-20
CA2531620A1 (en) 2005-01-20
HK1089667A1 (en) 2006-12-08
KR20060033785A (ko) 2006-04-19
GB0316127D0 (en) 2003-08-13
AU2004255024B2 (en) 2007-09-27
BRPI0412408A (pt) 2006-08-22
WO2005004872A1 (en) 2005-01-20
PT1653964E (pt) 2008-11-24
NZ544270A (en) 2007-09-28
PL1653964T3 (pl) 2009-01-30
US20060167024A1 (en) 2006-07-27

Similar Documents

Publication Publication Date Title
HK1078771A1 (en) Use of the quinazoline derivative zd6474 combined with gemcitabine and optionally ionising radiationin the treatment of cancer
MX2007003506A (es) Terapia de combinacion de cancer que comprende azd2171 e imatinib.
MX2007003505A (es) Combinacion que comprende zd6474 e imatinib.
CY1111547T1 (el) Συνδυασμος zd6474 και πεμετρεξεδης
CY1111482T1 (el) Συνδυασμος azd2171 και πεμετρεξεδης
HRP20080597T3 (en) Cancer combination therapy comprising azd2171 and zd1839
NO20064755L (no) Kombinasjonsterapi
NO20056171L (no) Kombinasjonsterapi
WO2005092384A3 (en) Combination therapy with azd2171 and a platinum anti-tumour agent
NO20064754L (no) Kombinasjonsterapi

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application